Edition:
United States

Sanofi SA (SASY.BE)

SASY.BE on Berlin Stock Exchange

87.92EUR
19 May 2017
Change (% chg)

-- (--)
Prev Close
€87.92
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
12,122
52-wk High
€92.65
52-wk Low
€67.00

Latest Key Developments (Source: Significant Developments)

Sanofi receives CHMP recommendation for approval of insulin lispro biosimilar
Friday, 19 May 2017 07:09am EDT 

May 19 (Reuters) - SANOFI SA :REG-SANOFI RECEIVES CHMP RECOMMENDATION FOR APPROVAL OF INSULIN LISPRO BIOSIMILAR.POSITIVE OPINION BASED ON A CLINICAL DEVELOPMENT PROGRAM INVOLVING OVER 1,000 PEOPLE WITH TYPE 1 OR TYPE 2 DIABETES.EUROPEAN COMMISSION IS EXPECTED TO MAKE A FINAL DECISION ON MARKETING AUTHORIZATION FOR INSULIN LISPRO SANOFI(® )IN COMING MONTHS.  Full Article

Frontier IP announces 250 mln euro licence option agreement with Sanofi
Tuesday, 9 May 2017 06:50am EDT 

May 9 (Reuters) - Frontier IP Group Plc ::Exscientia announces 250 mln euro collaboration for a multiple-product development and licence option agreement with Sanofi.  Full Article

Regeneron and Sillajen report immuno-oncology clinical study agreement
Monday, 8 May 2017 08:30am EDT 

May 8 (Reuters) - Sillajen Inc <215600.KQ>::Regeneron and Sillajen announce immuno-oncology clinical study agreement for combination treatment in kidney cancer.Regeneron - phase 1b clinical trial will evaluate combination of regeneron's pd-1 inhibitor regn2810 and Sillajen's pexa-vec, an oncolytic virus.Regeneron Pharmaceuticals - under terms of agreement, trial will be solely conducted, funded by sillajen based upon mutually developed study design.Regeneron Pharmaceuticals Inc - co, Sanofi is developing regn2810 both alone and in combination with other therapies for treatment of various cancers.Regeneron Pharmaceuticals- open-label trial for phase 1b dose-escalation study is expected to begin later this year.Regeneron Pharmaceuticals- phase 1b dose-escalation study will initially open in Korea, with expansion to sites in U.S..  Full Article

Regeneron and Inovio enter immuno-oncology clinical study agreement
Monday, 8 May 2017 07:30am EDT 

May 8 (Reuters) - Inovio Pharmaceuticals Inc : :Regeneron and Inovio enter immuno-oncology clinical study agreement for glioblastoma combination therapy.Regeneron Pharmaceuticals Inc - study will be conducted by inovio in patients with newly-diagnosed glioblastoma multiforme.Regeneron-Study to evaluate co's pd-1 inhibitor, regn2810, with Inovio's ino-5401 t cell activating immunotherapy encoding multiple antigens and ino-9012.Regeneron - trial will be solely conducted and funded by inovio, based upon a mutually agreed upon study design, and regeneron will supply regn2810.Regeneron Pharmaceuticals Inc - Inovio and regeneron will jointly conduct immunological analyses in support of study.Regeneron Pharmaceuticals Inc - Regeneron, in collaboration with Sanofi, is developing regn2810 both alone and in combination with other therapies.  Full Article

Sanofi Genzyme announces approval of Cerdelga by Health Canada for rare genetic condition
Monday, 1 May 2017 08:00am EDT 

May 1 (Reuters) - Sanofi Sa :Sanofi genzyme announces approval of cerdelga (eliglustat capsules) by health canada for rare genetic condition.  Full Article

Regeneron and Sanofi announce Kevzara license application resubmission for review by FDA
Friday, 28 Apr 2017 01:00am EDT 

April 28 (Reuters) - Sanofi :Regeneron and Sanofi announce Kevzara® (sarilumab) Biologics License Application resubmission accepted for review by U.S. FDA.Per Prescription Drug User Fee Act (PDUFA), new target action date is May 22, 2017.European Commission expected to make a final decision on marketing authorization application for Kevzara in EU in coming months.  Full Article

Sanofi and Regeneron announce FDA approval of a once-monthly dosing option for Praluent
Tuesday, 25 Apr 2017 08:00am EDT 

April 25 (Reuters) - Sanofi :Sanofi and Regeneron announce FDA approval of a new once-monthly dosing option for Praluent (alirocumab) injection.Sanofi and Regeneron announce FDA approval of a new once-monthly dosing option for Praluent (alirocumab) injection.Monthly dosing schedule now approved in both United States and European Union.  Full Article

Regeneron says FDA approved for praluent injection
Tuesday, 25 Apr 2017 08:00am EDT 

April 25 (Reuters) - Regeneron Pharmaceuticals Inc -:Regeneron and Sanofi announce FDA approval of a new once-monthly dosing option for Praluent (Alirocumab) injection.Regeneron and Sanofi announce FDA approval of a new once-monthly dosing option for Praluent (Alirocumab) injection.  Full Article

Sanofi receives FDA approval of Thymoglobulin for prevention of acute kidney transplant rejection
Monday, 24 Apr 2017 08:30am EDT 

April 24 (Reuters) - Sanofi SA ::Sanofi receives FDA approval of Thymoglobulin® for the prevention of acute kidney transplant rejection.Sanofi- FDA approved thymoglobulin for use in conjunction with concomitant immunosuppression in prophylaxis of acute rejection in patients receiving kidney transplant.  Full Article

EU Medicines Agency recommendations for April 2017
Friday, 21 Apr 2017 01:51pm EDT 

April 21 (Reuters) - EU Medicines Agency -:EU Medicines Agency recommendations for April 2017.EU Medicines Agency recommends approval granting of a marketing authorisation for Sandoz's Rixathon Non-Hodgkin's Lymphoma (NHL), chronic lymphocytic leukaemia.Recommends approval of Sanofi SA and Regeneron's Kevzara (Sarilumab) for treatment of rheumatoid arthritis.Recommends approval of Biogen Spinraza drug for spinal muscular atrophy drug.Recommends approval of Pfizer's Besponsa for treatment of acute lymphoblastic leukaemia.Recommends approval of Biomarin Neuronal Ceroid Lipofuscinosis drug.Recommends approval of GMP-Orphan SA's Cuprior for treatment of Wilson's disease.Recommends approval of Almirall's Skilarence for treatment of psoriasis.Recommends approval of Mylan S.A.S' Febuxostat Mylan for prevention and treatment of hyperuricaemia.  Full Article

More From Around the Web

BRIEF-Sanofi receives CHMP recommendation for approval of insulin lispro biosimilar

* REG-SANOFI RECEIVES CHMP RECOMMENDATION FOR APPROVAL OF INSULIN LISPRO BIOSIMILAR